Maitreya Medicare Ltd

On 26-Dec, Maitreya Medicare Ltd’s stock price fell sharply to ₹210.05, down ₹9.10 or 4.15%, hitting a new 52-week low of ₹208.10. This decline reflects a continuation of the company’s prolonged underperformance relative to market benchmarks and deteriorating financial fundamentals.

Maitreya Medica's historical performance has shown fluctuations, with net sales declining from 49.41 Cr in Mar'22 to 46.66 Cr in Mar'25, and profits decreasing significantly, while total assets and liabilities increased from 24.49 Cr to 47.99 Cr during the same period. Cash flow improved to 5.00 Cr in Mar'25 after a negative cash flow in Mar'24.

Maitreya Medica's historical performance shows declining net sales and profitability from March 2022 to March 2025, with net sales dropping from INR 49.41 crore to INR 46.66 crore and profit after tax decreasing from INR 4.25 crore to INR 1.87 crore. However, cash flow from operating activities improved to INR 5 crore in March 2025, indicating some operational recovery.

As of 17-Nov, Maitreya Medicare Ltd's stock price is at 260.55, down 9.07% and underperforming its sector. Despite a strong Debt to EBITDA ratio and rising delivery volume, the stock has seen a significant year-to-date decline of 22.49% due to a 40% drop in profits.

Maitreya Medica's historical performance has shown fluctuations, with net sales decreasing from INR 47.80 crore in March 2024 to INR 46.66 crore in March 2025, and declines in profitability metrics, while cash flow from operating activities improved to INR 5.00 crore. Overall, the company experienced variability in financial performance over the past four years.

As of 13-Nov, Maitreya Medicare Ltd is currently priced at 288.65, reflecting a 6.34% increase and strong short-term performance, significantly outperforming its sector. However, despite recent gains, the company faces long-term challenges with a 40% decline in profits over the past year.

Maitreya Medica's historical performance shows declining net sales and profits from Mar'22 to Mar'25, despite an increase in total assets and improved cash flow. Key metrics peaked in Mar'23 but have generally trended downward since then.

Maitreya Medica's historical performance shows declining net sales from INR 49.41 crore in March 2022 to INR 46.66 crore in March 2025, despite an increase in operating profit from INR 3.36 crore to INR 4.86 crore. Total assets and liabilities both rose significantly, while cash flow from operating activities improved from INR 0.00 crore to INR 5.00 crore.

As of 11-Nov, Maitreya Medicare Ltd's stock price is 245.60, up 3.5% today, with increased trading activity. However, it has a year-to-date decline of 26.94%, indicating long-term underperformance despite recent gains.

As of 06-Nov, Maitreya Medicare Ltd's stock price is declining at 230.90, down 2.72%, and has underperformed its sector and the benchmark Sensex significantly over the past year. The stock is trading below all major moving averages, with a notable drop in investor participation and a year-to-date decline of 31.31%.

Maitreya Medica's historical performance has shown fluctuating sales and profitability, with net sales declining from INR 49.41 crore in March 2022 to INR 46.66 crore in March 2025, while total assets increased significantly. Despite a drop in profit metrics, cash flow from operations improved to INR 5 crore in March 2025.

As of 28-Oct, Maitreya Medicare Ltd's stock price is at 237.00, down 4.63%, and has underperformed its sector and the broader market significantly. The company faces declining profits and negative growth indicators, leading to a year-to-date return of -29.50% and a negative investor sentiment.

As of 09-Oct, Maitreya Medicare Ltd's stock price is 254.70, up 8.61% today, but it has declined 35.03% over the past year. Despite strong debt servicing capabilities, the company faces declining profitability and poor long-term growth prospects.